New York, New York--(Newsfile Corp. - January 8, 2021) - COVAXX, a U.S. company developing a multitope, peptide-based vaccine to fight COVID-19, announced today that the company has initiated preclinical work on a second vaccine candidate to address the latest mutations of the SARS-CoV-2 responsible for COVID-19, and specifically the South African mutation.
New York, New York--(Newsfile Corp. - January 8, 2021) - COVAXX, a U.S. company developing a multitope, peptide-based vaccine to fight COVID-19, announced today that the company has initiated preclinical work on a second vaccine candidate to address the latest mutations of the SARS-CoV-2 responsible for COVID-19, and specifically the South African mutation.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- COVAXX has initiated preclinical work on a second vaccine candidate to address the latest mutations of the SARS-CoV-2 responsible for COVID-19, and specifically the South African mutation.
- COVAXX is well positioned to address mutations rapidly, with an accelerated path to the clinic
Contacts:
David Schull
2128454226
David.Schull@russopartnersllc.com
Diane Murphy
(310) 658.8756
diane@covaxx.com
Source: COVAXX
